PARK7/DJ1 Recombinant Rabbit Monoclonal Antibody [SN07-21] (ET1611-45)

UNIPROT #

Q99497

PROTEIN NAME

PARK7/DJ1

SYNONYMS

CAP1 antibody;DJ-1 antibody;DJ1 antibody;DJ1 protein antibody;Epididymis secretory sperm binding protein Li 67p antibody;FLJ27376 antibody;FLJ34360 antibody;FLJ92274 antibody;HEL S 67p antibody;Oncogene DJ1 antibody;OTTHUMP00000001348 antibody;OTTHUMP00000001349 antibody;OTTHUMP00000001350 antibody;OTTHUMP00000001351 antibody;PARK7 antibody;PARK7_HUMAN antibody;Parkinson disease (autosomal recessive, early onset) 7 antibody;Parkinson disease protein 7 antibody;Parkinson protein 7 antibody;Protein DJ-1 antibody;SP22 antibody

SEQUENCE SIMILARITIES

Belongs to the peptidase C56 family.

TISSUE SPECIFICITY

Highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart. Detected at slightly lower levels in placenta and brain (at protein level). Detected in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa. Expressed by pancreatic islets at higher levels than surrounding exocrine tissues.

DEVELOPMENTAL STAGE

In pancreatic islets, expression increases during aging.

POST-TRANSLATIONAL MODIFICATION

Sumoylated on Lys-130 by PIAS2 or PIAS4; which is enhanced after ultraviolet irradiation and essential for cell-growth promoting activity and transforming activity.; Cys-106 is easily oxidized to sulfinic acid.; Undergoes cleavage of a C-terminal peptide and subsequent activation of protease activity in response to oxidative stress.

SUBCELLULAR LOCATION

Cell membrane, Cytoplasm, Endoplasmic reticulum, Membrane, Mitochondrion, Nucleus.

FUNCTION

PARK7/DJ1 is a ubiquitously expressed protein involved in various cellular processes including cell proliferation, RNA-binding, and oxidative stress. The protein has been found to colocalize within a subset of pathologic tau inclusions in a diverse group of neurodegenerative disorders known as tauopathies. Defects in PARK7/DJ1 are the cause of autosomal recessive early-onset Parkinson's disease 7 (PARK7). Parkinson's disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years. The disease is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK7 is characterized by onset before 40 years and slow progression. It has also been suggested that PARK7/DJ1 is a mitogen dependent oncogene product involved in Ras related signal transduction pathways.